Developer of an online drug delivery platform designed to improve the supply chain of pharmaceuticals by completely digi
Developer of an online drug delivery platform designed to improve the supply chain of pharmaceuticals by completely digitizing the process.
Specialty Retail📍 Mumbai, IndiaFounded 2015
Current Valuation
$707.81M
as of 2023-Q4
PRIVATE
QL Price
$707.81M
0% vs last round
QuantLogix's current estimate for PharmEasy, published 2026-09-27 — in line with the last disclosed round of $707.81M (2023-Q4).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$707.81M
2023-Q4
weight 0.15
How this price has held up
No round has priced for PharmEasy since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, PharmEasy, 2026-09-27 (338af9c3b1c20e5d).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is PharmEasy going public?
No. PharmEasy is private and has not filed to go public. There is no S-1 on file.
What is PharmEasy's valuation in 2026?
PharmEasy is valued at $707.81M as of 2023-Q4, set by its Later Stage VC ($216.27M, Oct 2023). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has PharmEasy filed an S-1?
No public S-1 is on file for PharmEasy.
How much has PharmEasy raised?
PharmEasy has raised $2.1B in total, most recently a Later Stage VC of $216.27M in Oct 2023.
Is PharmEasy publicly traded — can you buy PharmEasy stock?
No. PharmEasy is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for PharmEasy on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2015
HQ
Mumbai, India
Employees
3,965
Total Raised
$2.1B
Last Round
Later Stage VC — $216.27M (Oct 2023)
IPO Status
private
Fundraising Status
Later Stage VC · $216.27M · 2y 11mo ago
privateTotal raised $2.1B
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Later Stage VC
$216.27M
Oct 2023
—
$707.81M
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for PharmEasy — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-19. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
+4% vs 2026-08
Open roles
28
via careers page
Product-build share
25%
engineering, research, product, design
Trajectory
steady
balanced build + GTM — 25% builders vs 75% go-to-market/G&A — scaling both sides.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
![Lab TestsLab Tests![Lab Tests UPTO 70% OFF![Can Sunscreen Cause Cancer? What the Research SaysVulnerability Disclosure PolicyLab Tests by Health Concern
Counted from PharmEasy's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CarePharmaceuticalWellnessHealth Diagnostics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2023-Q4. Refreshed quarterly.